Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aurovit is a multivitamin supplement, specifically a B-complex formulation containing vitamins B1, B2, B6, B12, nicotinamide (PP), and calcium pantothenate. In the context of oncology, it has been utilized as a supportive care intervention in clinical trials, most notably the **AUROVIT study** (NCT02544451) sponsored by the **Associazione Italiana Per Lo Studio Del Pancreas (AISP)**. This Phase II trial evaluated the efficacy and safety of the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. While Aurovit itself is not a primary antineoplastic agent, it is often administered to manage or prevent chemotherapy-induced peripheral neuropathy (CIPN), a common side effect of taxane-based therapies like nab-paclitaxel. The vitamins in the B-complex are essential for maintaining neuronal health and metabolic function, potentially mitigating the neurotoxic effects of cytotoxic drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aurovit.